Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Bose

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Cancer Research Communications|May 21, 2026
Interleukin-34 induced Arg1+ macrophages play a key role in breast cancer brain metastasisXiaoqing Cheng, Khooshbu K Patel, Brandon Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
JCO Precision Oncology|September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy TrialsPedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Nature Communications|November 16, 2018
Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Breast Cancer Research and Treatment|June 26, 2021
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancerFoluso O Ademuyiwa, Ina Chen, Jingqin Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Cancer Research Communications|May 21, 2026
Interleukin-34 induced Arg1+ macrophages play a key role in breast cancer brain metastasisXiaoqing Cheng, Khooshbu K Patel, Brandon Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast CancerCynthia X Ma, Ron Bose, Feng Gao, et al.
JCO Precision Oncology|September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy TrialsPedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Nature Communications|January 27, 2026
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trialTim Kong, Alex Mabry, Maureen Highkin, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Nature Communications|November 16, 2018
Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Breast Cancer Research and Treatment|June 26, 2021
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancerFoluso O Ademuyiwa, Ina Chen, Jingqin Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M Tolaney, Nabihah Tayob, Chau Dang, et al.
NPJ Breast Cancer|February 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trialRomualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, et al.
Pageof 8